دواعي استعمال تيسابري 300مجم فيال 300 مجم/15 مل

Tysabri: natalizumab 300 mg/15 mL concentrate vial for IV infusion (Biogen); for relapsing multiple sclerosis and Crohn's disease.

• Relapsing forms of multiple sclerosis (monotherapy)الفئة: AdultsDailyMed (U.S. National Library of Medicine)
• Moderately to severely active Crohn's disease with evidence of inflammation, inadequate response to or intolerance of conventional therapies and TNF-alpha inhibitorsالفئة: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (incidence >=10%) in MS: headache, fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea and rash.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Contraindicated in patients who have or have had PML, or who have had a hypersensitivity reaction to Tysabri.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic brain infection that usually leads to death or severe disability; risk increases with anti-JCV antibodies, longer treatment and prior immunosuppressant use.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Herpes encephalitis/meningitis and acute retinal necrosis, hepatotoxicity, hypersensitivity reactions (including anaphylaxis), immunosuppression/infections and thrombocytopenia have been reported.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Hematologic abnormalities (thrombocytopenia, anemia) have been reported in infants exposed in utero during the third trimester; monitor exposed newborns.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Natalizumab has been detected in human milk; effects on the breastfed infant are unknown.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)